Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
41
VTGN Quote, Financials, Valuation and Earnings
Last price:
$4.28
Seasonality move
:
20.93%
Day range:
$3.74 - $4.32
52-week range:
$1.90 - $5.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
130.92x
P/B ratio:
2.22x
Volume:
1.4M
Avg. volume:
718.6K
1-year change:
38.15%
Market cap:
$147.3M
Revenue:
$486K
EPS (TTM):
-$1.90
Analysts' Opinion
-
Consensus RatingVistagen Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.50, Vistagen Therapeutics, Inc. has an estimated upside of 288.74% from its current price of $3.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $3.73.
Fair Value
-
According to the consensus of 4 analysts, Vistagen Therapeutics, Inc. has 288.74% upside to fair value with a price target of $14.50 per share.
VTGN vs. S&P 500
-
Over the past 5 trading days, Vistagen Therapeutics, Inc. has underperformed the S&P 500 by -20.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vistagen Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vistagen Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Vistagen Therapeutics, Inc. reported revenues of $258K.
Earnings Growth
-
Vistagen Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Vistagen Therapeutics, Inc. reported earnings per share of -$0.54.
Enterprise value:
72M
EV / Invested capital:
1.06x
Price / LTM sales:
130.92x
EV / EBIT:
--
EV / Revenue:
78.36x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-1.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$247K
Return On Assets:
-67.18%
Net Income Margin (TTM):
-6698.8%
Return On Equity:
-76.57%
Return On Invested Capital:
-74.76%
Operating Margin:
-7772.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $810.5K | $875.7K | $919K | $183K | $258K | |
| Gross Profit | $44.4K | $278K | $247K | $26K | $73K | |
| Operating Income | -$35.7M | -$45.6M | -$65.2M | -$14.2M | -$20.1M | |
| EBITDA | -$34.9M | -$45M | -$64.5M | -$14.1M | -$19.9M | |
| Diluted EPS | -$4.71 | -$1.34 | -$1.90 | -$0.42 | -$0.54 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $96.3M | $36.8M | $39M | $99.9M | $78.9M | |
| Total Assets | $100.5M | $40.7M | $42.2M | $102.5M | $80.9M | |
| Current Liabilities | $7.9M | $6M | $2.9M | $7.5M | $13.6M | |
| Total Liabilities | $19.8M | $11.1M | $6.6M | $9.5M | $14.6M | |
| Total Equity | $80.7M | $29.6M | $35.6M | $93M | $66.3M | |
| Total Debt | $3.5M | $2.4M | $1.9M | $1.3M | $610K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31.5M | -$33.5M | -$53.8M | -$10.9M | -$13.8M | |
| Cash From Investing | -$540.8K | -$13.3M | -$9.1M | -$7.8M | -$94K | |
| Cash From Financing | $34.3M | $93.4M | $30.3M | -- | $27.7M | |
| Free Cash Flow | -$31.5M | -$33.7M | -$54M | -$10.9M | -$13.8M | |
VTGN
Sector
Market Cap
$147.3M
$28.4M
Price % of 52-Week High
72.57%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-21.44%
-1.32%
1-Year Price Total Return
38.15%
-22.19%
Beta (5-Year)
0.561
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.40
200-day SMA
Buy
Level
$2.98
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$4.25
Relative Strength Index (RSI14)
Buy
Level
51.22
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-79.2135
50-day SMA
Buy
Level
$4.05
MACD (12, 26)
Buy
Level
0.93
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.8446)
Sell
CA Score
(Annual)
Level (-1.1095)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (6.0905)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, VTGN has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VTGN average analyst price target in the past 3 months is $14.50.
-
Where Will Vistagen Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vistagen Therapeutics, Inc. share price will rise to $14.50 per share over the next 12 months.
-
What Do Analysts Say About Vistagen Therapeutics, Inc.?
Analysts are divided on their view about Vistagen Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vistagen Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Vistagen Therapeutics, Inc.'s Price Target?
The price target for Vistagen Therapeutics, Inc. over the next 1-year time period is forecast to be $14.50 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VTGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vistagen Therapeutics, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VTGN?
You can purchase shares of Vistagen Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vistagen Therapeutics, Inc. shares.
-
What Is The Vistagen Therapeutics, Inc. Share Price Today?
Vistagen Therapeutics, Inc. was last trading at $4.28 per share. This represents the most recent stock quote for Vistagen Therapeutics, Inc.. Yesterday, Vistagen Therapeutics, Inc. closed at $3.73 per share.
-
How To Buy Vistagen Therapeutics, Inc. Stock Online?
In order to purchase Vistagen Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VTGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VTGN
Sector
P/E ratio
--
23.66x
PEG ratio
-0.10x
-0.01x
P/B ratio
2.22x
1.84x
Price / LTM sales
130.92x
1.60x
Growth Metrics
VTGN
Sector
Revenue growth
207.14%
4.85%
Earnings growth
-54.89%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.44
-$0.20
Profitability
VTGN
Sector
Profitability FY 2024
-$149K
$3.6M
Return on invested capital
-74.76%
-30.98%
Return on assets
-67.18%
-27.62%
Return on equity
-76.57%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
12
Balance Sheet
VTGN
Sector
Total cash
$77.2M
$27.2M
Short term investments
$13.4M
$25.7M
Total assets
$84.3M
$79.9M
Long term debt
$610K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
